These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 25625172)
1. Cape Town connections. Dumiak M IAVI Rep; 2014; 18(4):4-10. PubMed ID: 25625172 [No Abstract] [Full Text] [Related]
2. New center focuses on neutralizing antibodies. McEnery R IAVI Rep; 2008; 12(5):15. PubMed ID: 20210066 [No Abstract] [Full Text] [Related]
3. HIV vaccine design: the neutralizing antibody conundrum. Stamatatos L Curr Opin Immunol; 2012 Jun; 24(3):316-23. PubMed ID: 22595693 [No Abstract] [Full Text] [Related]
4. Antibodies: beyond neutralization. von Bubnoff A IAVI Rep; 2010; 14(1):8-12. PubMed ID: 20349583 [No Abstract] [Full Text] [Related]
5. HIV vaccine development--improving on natural immunity. Johnston MI; Fauci AS N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447 [No Abstract] [Full Text] [Related]
6. Infectious disease. An enterprising time for HIV vaccine research. Cohen J Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300 [No Abstract] [Full Text] [Related]
7. South African AIDS Vaccine Initiative launches phase I trial. Kresge KJ IAVI Rep; 2009; 13(4):19. PubMed ID: 20225578 [No Abstract] [Full Text] [Related]
8. Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost. Dumiak M IAVI Rep; 2014; 18(2):4-7, 17. PubMed ID: 25105201 [No Abstract] [Full Text] [Related]
9. Current world literature. Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137 [No Abstract] [Full Text] [Related]
10. The RV144 Thai HIV vaccine trial. Plotkin SA Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337 [No Abstract] [Full Text] [Related]
11. The HVTN 503/Phambili study: efficacy is always the issue. Dhesi Z; Stebbing J Lancet Infect Dis; 2011 Jul; 11(7):490-1. PubMed ID: 21570356 [No Abstract] [Full Text] [Related]
12. In pursuit of an HIV vaccine: an interview with Andrew McMichael. McMichael AJ BMC Biol; 2013 May; 11():60. PubMed ID: 23692824 [No Abstract] [Full Text] [Related]
13. Cure of HIV infection: is the long wait over? Shearer WT J Allergy Clin Immunol; 2014 Jul; 134(1):20-2. PubMed ID: 25117800 [No Abstract] [Full Text] [Related]
14. [The new vaccine challenges of "humanization" of HIV]. Nau JY Rev Med Suisse; 2013 Aug; 9(394):1490-1. PubMed ID: 24024395 [No Abstract] [Full Text] [Related]
15. New mouse models provide insights into how to design a more effective HIV vaccine. Harper KN AIDS; 2017 Jan; 31(3):N3-N4. PubMed ID: 28002067 [No Abstract] [Full Text] [Related]
16. Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. Parsons MS; Rouleau D; Routy JP; LeBlanc R; Grant MD; Bernard NF AIDS; 2011 Jun; 25(10):1249-64. PubMed ID: 21516028 [TBL] [Abstract][Full Text] [Related]
17. RV144: old vs. new. Weiner DB Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335 [No Abstract] [Full Text] [Related]
18. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa. Slack CM Am J Bioeth; 2011 Jun; 11(6):21-2. PubMed ID: 21678209 [No Abstract] [Full Text] [Related]
19. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Ackerman ME; Dugast AS; Alter G Annu Rev Med; 2012; 63():113-30. PubMed ID: 22077718 [TBL] [Abstract][Full Text] [Related]
20. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Hope TJ Nat Med; 2011 Oct; 17(10):1195-7. PubMed ID: 21988997 [No Abstract] [Full Text] [Related] [Next] [New Search]